MT-0169
- Generic Name
- MT-0169
- Drug Type
- Biotech
- Background
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT06522373
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04017130
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Vanderbilt University Medical Center- Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Miami University, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath